Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II melphalan percutaneous hepatic perfusion for unresectable liver metastases from uveal melanoma
NL-OMON44964Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in intraocular melanoma and hepatic metastasis, sponsored by Leiden University Medical Center. Primary endpoints: Objective response rate and Conversion to resectability. Started Sep 2013; status: recruiting.
02
Drugs
melphalan
03
Conditions
intraocular melanomahepatic metastasis
Beyond the preview
Go deeper on NL-OMON44964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44964.